Skip to main content

Table 1 Baseline characteristics of the PP patients enrolled in the three treatment groups of the trial

From: A randomized controlled phase IIb wound healing trial of cutaneous leishmaniasis ulcers with 0.045% pharmaceutical chlorite (DAC N-055) with and without bipolar high frequency electro-cauterization versus intralesional antimony in Afghanistan

  Per protocol (PP) evaluation Test
Group I Group II Group III Total p-value  
Male 13 8 11 32   Pearson Chi-Square
Female 10 15 12 37 0.372* Test (Exact-Sig.)
Age (95% CI) 26 (19-34) 28 (22-33) 33 (25-40) 29 (25-33) 0.308* Kruskal-Wallis Test
Lesion age (95% CI) 9 (7-11) 8 (7-10) 7 (6-9) 8 (7-9) 0.437* Kruskal-Wallis Test
Lesion size (95% CI) 3.7 (2.3-5.0) 2.5 (1.7-3.3) 3.0 (2.0-4.1) 3.1 (2.5-3.7) 0.421* Kruskal-Wallis Test
Parasite species       
L. major 4 5 7 16   
L. tropica 5 13 10 28   Pearson Chi-Square
Not determined 14 5 6 25 0.664* Test (Exact-Sig.)
Lesion location       
Head 5 3 2 10   
Trunc 0 0 1 1   
Upper extr. 12 16 14 42   Pearson Chi-Square
Lower extr. 6 4 6 16 0.666* Test (Exact-Sig.)
Parasite load according to Giemsa staining       
Low (+) 12 11 8 31   
Moderate (++) 8 12 14 34   
High (+++) 1 0 1 2   Pearson Chi-Square
Not determined 2 0 0 2 0.541* Test (Exact-Sig.)
Biopsy prior to treatment       
Evaluable 16 18 17 51   Pearson Chi-Square
Not evaluable 7 5 6 18 0.940* Test (Exact-Sig.)
Parasite load/g tissue (SEM) 2.944 (1.645) × 106 3.081 (1.980) × 106 2.773 (1.785) × 106 2.935 (1.032) × 106 0.636* Kruskal-Wallis Test
  1. Statistical tests were used as indicated (p < 0.05 indicates a significant proportion, *p-values refer to observations with complete information).